Europe's largest drugs company, GSK, is starting the registration process for a meningitis vaccine to be used at low prices in Africa.
Globorix will only be used in Africa to prevent meningitis at prices that may never cover its research costs.
The new vaccine will cost more than $400 million to develop, but will only be sold and used in Africa.
The vaccine is aimed at meningitis A and C and will succeed an older vaccine called Titanrix - which covered hepatitis B, tetanus, whooping cough, and diphtheria and haemophilus influenza.
Early this year, more than 110 people died of meningitis 3.000 cases, prevalently in the districts of Adjumani, Arua and Nebbi were also reported.